DARWIN EU® – Trends in utilisation of Attention-Deficit Hyperactivity Disorder (ADHD) Medications

Study type

• Study topic:
  Human medicinal product
• Study type:
  Non-interventional study
• Data collection methods:
  Secondary use of data

Non-interventional study

• Non-interventional study design:
  Cohort

Study drug and medical condition

• Name of medicine:
  LISDEXAMFETAMINE
• Name of medicine, other:
  Methylphenidate, Atomoxetine, Dexamphetamine, Guanfacine

Population studied

• Short description of the study population:
  Population-level utilisation of ADHD medications: general population; All people aged 3 years and older [1], registered in the respective databases since the 1st of January of 2010 to the latest available data, with at least 365 days of prior data availability, will participate in the population-level analysis of period prevalence and incidence of ADHD medications of interest. ; Patient-level utilisation of ADHD medications: new user cohort; In objectives 3 and 4, incident user cohorts of any ADHD medication, as well as each ADHD medication, will be created, using a 365-day washout window. ;

Study design details

• Study design:
  Cohort studies will be conducted using routinely collected health data from six databases.
• Main study objective:
  To estimate the monthly and yearly period prevalence of use of each ADHD medicine, overall and stratified by age and sex in each database. ; 2. To estimate the monthly, and yearly incidence of use of each ADHD medicine, overall and stratified by age and sex in each database. ; 3. Among incident users of each ADHD medicine, to identify the indication at the time of the initial prescribing/dispensing, overall and stratified by age and sex. ; 4. Among incident users of each ADHD medicine, to estimate the initial dose, cumulative dose, and time on treatment of the initial medication, overall and stratified by age and sex.; 5. Among new users of any ADHD medicine, to estimate the total treatment duration, number of prescriptions overall and by medicine, stratified by initial medicine.; 6. To identify the treatment pathway of each individual who initiated an ADHD medicine, including treatment add-on, switch, and concurrent medication/co-prescribing, stratified by calendar year of initiation, age group, and sex. ;